This Seattle startup is planning to mine on the moon. It could bring nuclear fusion closer to reality
Humans have long been transfixed by the moon, awed and inspired by its reassuring presence in the night sky and its influence on the tides. In recent decades, though, our fascination with our nearest celestial neighbor has become somewhat more opportunistic: The moon contains valuable resources, and governments and companies are eager to get their hands on them.
One such resource is helium-3 (He-3), a gas that some experts say could unlock clean and abundant energy on Earth as a fuel for fusion. It's this gas that Interlune, a Seattle-based startup, has its sights on. The company wants to be the first to commercialize space resources, starting with He-3, which it plans to begin harvesting from the moon and selling on Earth by the end of the decade.
Helium-3 is used mostly in medical diagnostics and national security, but it has great potential to unlock groundbreaking technological advancements, the most tantalizing of which is nuclear fusion. Fusion is what powers the stars, and as the climate crisis deepens, scientists are desperately trying to harness it in reactors to produce abundant energy without the use of fossil fuels. He-3 is a desirable fuel for fusion reactors because it would produce very little dangerous radioactive waste.
'Helium-3 fusion reactors open up the opportunity to have power available for people on Earth in a way that's never been available before,' says Aaron Olson, a research physicist at NASA's Kennedy Space Center who has studied helium-3 extraction. 'And that's not only for those of us who happen to live in areas where we have grids that function really well, but it could bring energy to people who live in areas like sub-Saharan Africa, where 90% of the population doesn't have access to electricity.'
The problem is that He-3 is extremely rare on Earth, and therefore very expensive. A kilogram of the stuff will set you back roughly $20 million. Most of the terrestrial supply comes from the decay of tritium, which is a byproduct of nuclear reactors and aging nuclear weapons. The United States has been rationing He-3 since 2010.
By contrast, the moon holds an abundance of He-3. The isotope is emitted from the sun's corona and carried through the solar wind, and because the moon isn't protected by an atmosphere or magnetic field, these particles have been embedding themselves in the lunar soil—or regolith—for billions of years. Recent estimates suggest the moon has about 1.1 million metric tons of He-3, compared to Earth's reserves of just 1.6 tons. 'Helium-3 is the only resource worth going all the way to the moon and back for,' Interlune's director of business development, Nina Hooper, explained. 'Now it's up to us to go develop the technology that's going to help us extract it.'
Interlune's plan is to send its ' harvesters ' to an area that's about a mile wide and located near the moon's equator on its near side, or the side that's always visible to Earth. These unmanned machines will dig into the top three meters of lunar regolith, crush the rocks, extract the He-3 gas, and then put the regolith back where it belongs. 'When we're done, it looks like a tilled field,' says Interlune CEO and cofounder Rob Meyerson, who previously served as president of Blue Origin.
Interlune is aiming to start with two test missions, one in 2027 and another in 2029, to measure He-3 levels on the moon, harvest it on a small scale, and bring some back to Earth. It wants to go to market with 20 kilograms of He-3 in 2030, ramping up to 100 kilograms over five years. 'That will do a great job to stabilize the supply chain,' Meyerson adds.
Could it also unlock the future of clean energy? Despite promising advances in fusion science, commercial fusion is still a ways off. 'There is still a lot of work to be done before a functional reactor goes online,' says NASA's Olson. 'There are still questions that persist as to how quickly that can happen.' An abundance of He-3 for fusion research could, however, help speed up that process.
In the meantime, Interlune has another sector in mind for its first target market: quantum computing. This market is projected to balloon between now and 2030, with big tech players like IBM, Nvidia, and Apple pouring billions into quantum tech research and development with the hopes of creating breakthrough innovations and rapidly solving stubborn problems across science, medicine, and other fields.
Helium-3 helps keep these supercomputers cool enough to function efficiently, and Meyerson says Interlune has already secured contracts with 'more than one' company and letters of intent for 'more than a billion dollars' worth of He-3 even before it has demonstrated its technology. 'These customers are relatively price insensitive, so they're willing to pay something near the current market price, and they're really, really eager to secure supply,' he says.
This week, Interlune announced Maybell Quantum, a quantum infrastructure company, as its first commercial customer. Maybell agreed to buy 'thousands of liters' of He-3 to be delivered between 2029 and 2035. The U.S. Department of Energy has also agreed to buy He-3 from Interlune in its quest to top up its reserves.
Not everyone is eager to see the moon become an industrial hub, though. Astronomers are particularly worried about mining because the moon is an important outpost for space science thanks to how quiet, still, and cold it is. For example, the far-side of the moon is 'the most radio quiet part of the inner solar system,' explains Richard Green, an astronomer emeritus at the University of Arizona's Steward Observatory and a vocal advocate for preserving lunar science. That makes it the best place to use radio astronomy to learn about the universe and look for signs of life beyond Earth. 'If the mining equipment is next door and blasting rocks and digging things up, that would just be inconsistent with the stable platform that those really sensitive detections need,' Green adds.
He and other researchers want to see the creation of an international system that evaluates claims to certain regions on the moon and allows scientists to 'reserve' sites in advance so they can study the area before any mining takes place. 'It's not that there's anything wrong with mining, it's a legitimate activity,' he says. 'But so is science. How do we set up a system of communication and coordination that doesn't lead to conflict?'
The existing rules around space mining are fairly new, and don't offer much help. A 2015 U.S. law ruled that private American companies can own any space resources they mine. In 2020, NASA's Artemis Accords sought to introduce some guidelines on the practice of harvesting space resources, stating that any extraction must be done in compliance with the 1967 Outer Space Treaty. That means countries carrying out mining would have to do so for the benefit of all mankind. They'd have to avoid 'harmful contamination of space and celestial bodies,' and would be liable for any damage they cause.
All of that said, regulations might be hard to enforce. 'There are no police that are going to land on the moon,' says Green. (Neither China nor Russia have signed onto the Artemis Accords, which aren't legally binding anyway.)
Meyerson is quick to underscore that what Interlune wants to do isn't traditional mining. 'There are no chemicals used to strip the helium-3 out of the material,' he says. 'You're not leaving contaminated tailings behind. So as far as comparing this to mining, it's just 180 degrees apart.' He believes that by being the first to harvest moon resources, Interlune can set the standard as the lunar gold rush accelerates.
Eventually, Interlune plans to expand its scope to harvest other lunar resources that could be used to build infrastructure and produce rocket fuel on the moon, all of which could serve as a stepping stone for future space exploration. 'We're in this for the long run of building an in-space economy,' says Meyerson. 'We would be processing other resources on the moon, like water that we can turn into rocket fuel, metals like aluminum and titanium and silicon, and then construction material.'
Some proponents of space mining also argue it's an environmental Hail Mary. 'There is the notion of the Earth becoming an oasis,' says Olson. 'It's an idea that harvesting resources, whether it be the moon or other places in space, could help us preserve the Earth for future generations in a way where maybe we're not doing as much damaging extractive work on Earth, and some of that could be put in places that are, for lack of a better term, barren.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
20 minutes ago
- Bloomberg
Novo Nordisk's CagriSema Shot Tied to Greater Weight Loss at Lower Doses
Novo Nordisk A/S's next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly, patients who chose to stick with a lower dose lost more weight on average. The studies allowed patients to stop at lower doses of the drug, an unusual option in a trial. Researchers presenting new data Sunday at the American Diabetes Association meeting in Chicago say the findings offer clues as to how the drug would be used in real life. There's a group of people who respond very well to this medicine, said Timothy Garvey, director of the Diabetes Research Center at the University of Alabama at Birmingham, who helped lead the trials.
Yahoo
34 minutes ago
- Yahoo
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
By Deena Beasley (Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical program is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's® (ADA) 85th Scientific Sessions and published in NEJM. "In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. "These results reinforce our confidence in CagriSema and we continue to study the potential of this combination through the REDEFINE trials." CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7]; p<0.001) if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group (estimated difference [95% CI] -17.3 [-18.1 to -16.6]; p<0.001).1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI <30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group, 10.2% reached that threshold at 68 weeks.1 Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body-weight reduction of ≥25% ([95% CI] 39.5 (37.1 to 41.9); p<0.001).* Additionally, 23.1% lost ≥30% of their body weight ([95% CI] 22.7 (20.7 to 24.7); p<0.001).1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction ([95% CI] 33.7 (31.5 to 35.9); p<0.001) and 19.3% achieved ≥30% body-weight reduction ([95% CI] 18.9 (17.1 to 20.7); p<0.001).1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus -5.7% and -4.3% for the placebo group, respectively. "In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions," said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. "Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement." Safety data generated in the REDEFINE 1 and 2 trials was comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), vomiting (26.1% vs 4.1%) and were mostly transient and mild-to-moderate in severity.1 Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM.3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was -15.7% with CagriSema versus -3.1% with placebo (estimated difference [95% CI] -12.6% [-13.4 to -11.7]; p<0.001).3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was -13.7% with CagriSema versus -3.4% with placebo (estimated difference [95% CI] -10.4% [-11.2 to -9.5]; p<0.001).3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by >5% (83.6% vs 30.8% of participants; p<0.001), ≥10% (65.6% vs 10.3%), ≥15% (43.9% vs 2.4%), and ≥20% (22.9% vs 0.5%; p<0.001).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3 The REDEFINE clinical program will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand: this estimand estimates what the effect would be if all participants adhered to treatment** Based on the treatment policy estimand: treatment effect regardless of treatment adherence About CagriSemaCagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss. About the REDEFINE clinical trial programREDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight. Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2. About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.9,10 In the US, about 40% of adults live with obesity.11 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References: Garvey T, Blüher M, Contreras C, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;10.1056/NEJMoa2502081. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: Davies M, Bajaj H, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;10.1056/NEJMoa2502082. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
